Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH With its Oral Insulin Capsule

Nov. 14, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH). The proposed three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Oramed plans on initiating the study in the coming month.

For more information, see:  http://www.oramed.com/oramed-receives-regulatory-approval-to-conduct-clinical-study-for-treatment-of-nash-with-its-oral-insulin-capsule/

Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Hide Buttons